ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Oncology and Hematology News and Journal Articles

Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise

Phillip L. Palmbos, MD, PhD, and Maha H. Hussain, MD
This article will review how PARP inhibitors function as a class, review the molecular features that sensitize cancer cells to this therapy, and discuss the data supporting its potential for patients with prostate cancer.

Recent Content

A new study has suggested two new ways to report on adverse events in the era of molecularly targeted therapies.

A phase II trial found that cabozantinib offers significantly better progression-free survival over sunitinib in patients with untreated advanced RCC.

People who carry a germline breast cancer susceptibility mutation can still substantially lower their risk of developing breast cancer, according to a new study.

This acute lymphocytic leukemia (ALL) slide show features blood smears showing mature and immature lymphocytes, and bone marrow biopsies with ALL involvement.

The higher incidence of bladder cancer in the Northeast in the last 50 years may be attributed to the presence of arsenic in the drinking water, according to a new study.

The UK Lung Cancer Screening Trial found that a low-dose CT screening program targeting high-risk individuals can find lung cancer at early stages.

The use of ADT along with modern dose-escalated RT does not improve survival vs RT alone in men with favorable intermediate-risk prostate cancer.

By clicking Accept, you agree to become a member of the UBM Medica Community.